The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested identity is unambiguous: human MAPK7 encodes mitogen-activated protein kinase 7, conventionally called ERK5 or BMK1, and corresponds to UniProt Q13164. The canonical protein is an 816-amino-acid conventional CMGC-family serine/threonine MAP kinase. Its N-terminal catalytic region and activation-loop TEY motif align with the supplied kinase-family/domain annotation; its unusually long C-terminal extension adds nuclear-localization/export, regulatory, and transcriptional-transactivation functions not present to the same extent in ERK1/2. No conflicting gene with a similar symbol was used in this report. (fernandez2021resumendetesis. pages 64-68, paudel2021themek5erk5pathway pages 1-2, pearson2018regulationoferk5 pages 9-13)
The best-supported primary annotation is: MAPK7/ERK5 is a stimulus-regulated, proline-directed protein Ser/Thr kinase and kinase–transcriptional regulator that relays MEKK2/3–MEK5 signals to cytoplasmic and nuclear substrates, especially MEF2-dependent endothelial stress and mechanotransduction programs. Its clearest indispensable physiological role is maintenance of endothelial survival, vascular development, and adult vascular integrity. (paudel2021themek5erk5pathway pages 1-2, tusa2023pathophysiologicalimpactof pages 4-6, paudel2021themek5erk5pathway pages 3-5)
| Annotation category | Best-supported conclusion | Key evidence / experimental basis | Confidence or caveat |
|---|---|---|---|
| Identity and architecture | Human MAPK7 encodes ERK5/BMK1 (UniProt Q13164), an 816-aa CMGC-family MAP kinase with an N-terminal kinase domain and unusually long regulatory C-terminal extension containing docking, nuclear-localization/export, and transcriptional-activation elements. | Concordant human sequence annotation, domain mapping, and biochemical literature; no conflicting same-symbol protein was identified. | High. Exact boundaries of some regulatory motifs vary among reports and isoforms. |
| Catalytic function and specificity | ERK5 catalyzes ATP-dependent transfer of phosphate to serine or threonine residues in protein substrates. Like conventional MAPKs, it preferentially recognizes proline-directed Ser/Thr-Pro sites, while docking interactions and cellular localization provide additional specificity. | Protein-kinase family chemistry, ERK5 biochemical assays, conserved MAPK catalytic motifs, and common-docking-region studies. | High for kinase chemistry; moderate for a universal sequence consensus because docking and context strongly influence substrate selection. |
| Upstream activation | The core cascade is MEKK2/MEKK3 → MEK5/MAP2K5 → ERK5. MEK5 directly activates ERK5 by dual phosphorylation of its activation-loop TEY motif; activated ERK5 then autophosphorylates sites in its C-terminal tail. | Kinase assays, phosphosite analysis, dominant-negative/constitutively active constructs, pathway-complex studies, and genetic disruption of MEK5 or MEKK2/3. | High. MEK5 is the established direct MAP2K; which MAP3K dominates depends on stimulus and cell type. |
| Localization and shuttling | Inactive ERK5 is predominantly cytoplasmic and conformationally restrained. TEY phosphorylation and C-terminal autophosphorylation promote an open conformation, release from HSP90–CDC37, exposure of the NLS, and nuclear accumulation; an NES supports return or retention in the cytoplasm. | Fractionation, microscopy, NLS/NES deletion constructs, phosphomutants, inhibitor-binding studies, and analysis of C-terminal truncations. | Moderate–high. Localization is dynamic, isoform- and context-dependent; kinase inhibitors can drive nuclear entry without physiological activation. |
| Direct and established outputs | MEF2C and MEF2D are well-supported ERK5-responsive transcription factors. ERK5 also regulates AP-1-associated factors such as c-JUN, c-FOS, and FRA-1, while its C-terminal transactivation domain can enhance transcription independently of substrate phosphorylation. | In-vitro phosphorylation, reporter assays, mutagenesis, nuclear-translocation studies, and genetic/pharmacological perturbation. | High for MEF2 regulation; moderate for some proposed targets because direct phosphorylation is not always separated from indirect transcriptional effects. |
| KLF2/KLF4 programs | In endothelial cells, flow-activated ERK5–MEF2 signaling induces KLF2 and KLF4, supporting quiescent, anti-inflammatory, anti-apoptotic, barrier-protective, and anti-EndMT programs. | Laminar-flow experiments, MEK5/ERK5 perturbation, MEF2 dependence, KLF-expression assays, and endothelial functional studies. | High for pathway-level regulation; these transcription factors should not be labeled direct ERK5 phosphorylation substrates without specific evidence. |
| Endothelial physiology | ERK5 is a major mechanotransduction and stress-response kinase in vascular endothelium, coupling laminar shear and mitochondrial ROS to survival, antioxidant signaling, reduced permeability, and vascular homeostasis. | Cultured endothelial flow systems, dominant-negative and constitutively active pathway components, apoptosis/barrier assays, and conditional mouse genetics. | High, but effects may differ under disturbed flow, disease, or cell-specific conditions. |
| Knockout phenotypes | Global or endothelial Erk5 loss in mice disrupts cardiovascular development, vessel maturation, and endothelial integrity, causing embryonic death around E9.5–E10.5. Adult endothelial deletion causes leakage, hemorrhage, endothelial apoptosis, and death within approximately 2–4 weeks; cardiomyocyte-specific loss is much less severe. | Independent germline and conditional knockout studies with developmental, histological, and survival analyses. | High. Severe genetic-loss phenotypes need not be reproduced by short-term catalytic inhibition because ERK5 also has noncatalytic functions. |
| Recent finding: oxidative stress | A 2023 synthesis highlighted ERK5 as a recurring antioxidant-response node linking ROS and shear stress to KLF2/KLF4 and NRF2, while emphasizing that its effects can be protective or pathogenic depending on context. | Integration of endothelial, cardiovascular, respiratory, hematopoietic, renal, and nervous-system experiments. | Moderate–high. This is a mechanistic literature synthesis rather than a single quantitative clinical study. |
| Recent finding: pluripotent stem cells | A 2024 human pluripotent-stem-cell study found that ERK5 sustains autocrine NODAL/TGF-β, WNT, FGF, and BMP signaling needed for balanced lineage specification. Inhibition or MAPK7 knockdown reduced NANOG-associated programs and biased differentiation toward ectoderm; recombinant NODAL partially rescued selected effects. | H1 human embryonic stem cells, two inhibitors, shRNA, RNA-seq time courses, directed differentiation, rescue experiments, and teratoma assays; most assays used three independent experiments. | Moderate. Primarily in-vitro evidence; limited replicate numbers constrain quantitative generalization. |
| Recent finding: cartilage mechanobiology | A 2024 cultured-chondrocyte study reported that low fluid shear stress (≤2 dyn/cm²) protected against IL-1β-induced apoptosis through suppression of miR-143-3p and activation of an ERK5–KLF4 axis. | Flow cytometry, Hoechst staining, immunoblotting, qPCR, miRNA mimics/inhibitors, ERK5 inhibition, and KLF4 overexpression. | Moderate. Directional mechanistic evidence is stronger than quantitative or clinical evidence; in-vivo replication is needed. |
| Recent finding: cancer systems | Recent work supports context-dependent roles in tumor metabolism, drug adaptation, and immune state, including an ERK5–PFKFB3 glycolytic vulnerability in pediatric diffuse midline glioma and an association of MAPK7–NF-κB signaling with T-cell recruitment and anti-PD-1 sensitivity in a 207-specimen pan-melanoma study. | Genetic/pharmacological tumor models, metabolic assays, multi-omics profiling, and immunotherapy-cohort analysis. | Moderate. These findings support biomarkers and hypotheses, not an approved MAPK7-directed therapy; association does not prove therapeutic benefit from inhibition. |
| Translational status and inhibitor paradox | MAPK7 is a preclinical, not clinically validated, drug target. Research compounds include BIX02188/BIX02189, XMD8-92, ERK5-IN-1, AX15836, JWG-071, and BAY-885. Several ATP-site inhibitors paradoxically expose the NLS, drive nuclear localization, and activate the C-terminal transcriptional domain despite blocking kinase activity. | Target-engagement assays, inhibitor-resistant mutants, structural/conformational studies, transcriptional reporters, and comparisons of chemical inhibition with genetic ablation. | High for the paradox; low clinical maturity. Off-target activity is common, kinase inhibition may not phenocopy MAPK7 loss, and no confirmed interventional trial directly targeting MAPK7/ERK5 was identified. |
Table: Compact evidence-based annotation of human MAPK7/ERK5 (Q13164), spanning molecular function, pathway position, localization, physiological roles, recent findings, and translational limitations.
Human MAPK7/ERK5 is reported as an approximately 98–110-kDa, 816-residue protein. Its N-terminal half contains the protein-kinase domain, MEK5-interaction region, oligomerization determinants, MAPK common-docking region, and activation-loop TEY sequence. Reported boundaries vary somewhat by source, but a representative mapping places the kinase region around residues 78–406, the common-docking region around 350–358, and the activation motif around residues 218–221 depending on numbering convention. The important conserved fact is dual phosphorylation of the threonine and tyrosine in the TEY motif. (fernandez2021resumendetesis. pages 64-68, paudel2021themek5erk5pathway pages 1-2, pearson2018regulationoferk5 pages 9-13)
The approximately 400-residue C-terminal extension distinguishes ERK5 from most conventional MAPKs. It contains proline-rich regions, an MEF2-interacting region, a nuclear-localization signal, a nuclear-export element, and a transcriptional activation domain. The tail is both regulatory and functional: it can restrain the kinase in the inactive conformation, becomes autophosphorylated after activation, controls nucleocytoplasmic shuttling, and can stimulate transcription. Thus, MAPK7 is not adequately described as only an ATP-site kinase. (fernandez2021resumendetesis. pages 68-72, pearson2018regulationoferk5 pages 9-13, monti2022clinicalsignificanceand pages 1-2)
ERK5 catalyzes the standard protein-kinase reaction:
ATP + protein-L-serine/threonine → ADP + phosphoprotein-L-serine/threonine.
As a conventional MAPK, it preferentially phosphorylates serine or threonine followed by proline, but a short sequence motif is not sufficient to define physiological substrates. Specificity also depends on MAPK docking interactions, scaffolding, stimulus, expression state, and whether ERK5 is cytoplasmic or nuclear. The common-docking region and substrate docking motifs therefore help discriminate physiological partners from peptides that can merely be phosphorylated in vitro. (fernandez2021resumendetesis. pages 64-68, drew2012mek5erk5pathwaythe pages 2-4)
The core module is:
MEKK2/MEKK3 → MEK5/MAP2K5 → ERK5/MAPK7.
MEK5 is the established direct MAP2K for ERK5. Activated MEK5 phosphorylates both residues of ERK5’s TEY activation loop; this induces full catalytic activation and permits C-terminal autophosphorylation. PB1-domain-mediated assembly contributes to specificity in the upstream MEKK2/3–MEK5 complex. Which MAP3K dominates varies with stimulus and cellular context. Reported activators include EGF and other mitogens, cytokines, oxidative and osmotic stress, and fluid shear stress. Ras participation is context-dependent and should not be treated as universally required. (paudel2021themek5erk5pathway pages 1-2, fernandez2021resumendetesis. pages 68-72, drew2012mek5erk5pathwaythe pages 2-4)
MEF2C and MEF2D are among the best-supported ERK5-responsive nuclear factors. ERK5-dependent MEF2 signaling promotes expression of genes such as KLF2, KLF4, and JUN in appropriate contexts. AP-1-associated proteins and transcriptional regulators—including c-JUN, c-FOS, FRA-1, c-MYC, and Sap1a—have also been placed downstream, although the literature does not always distinguish direct ERK5 phosphorylation from indirect transcriptional regulation. KLF2 and KLF4 should consequently be annotated principally as pathway outputs, not automatically as direct phosphosubstrates. (paudel2021themek5erk5pathway pages 3-5, pearson2018regulationoferk5 pages 13-18, drew2012mek5erk5pathwaythe pages 5-7)
ERK5 also possesses a C-terminal transcriptional activation domain. Consequently, gene regulation can involve both phosphorylation of other transcription factors and kinase-independent or partly kinase-independent action of ERK5’s own tail. This dual activity explains why ATP-site inhibition and complete MAPK7 depletion can produce different phenotypes. (monti2022clinicalsignificanceand pages 1-2, lochhead2020paradoxicalactivationof pages 2-3)
MAPK7 acts in both the cytoplasm and nucleus; it is neither secreted nor a membrane transporter. In resting cells, its C-terminal tail folds against the kinase region, and HSP90–CDC37 contributes to cytoplasmic retention. MEK5-dependent TEY phosphorylation and subsequent C-terminal autophosphorylation favor an open conformation, release from chaperones, exposure of the NLS, and nuclear accumulation. The NES supports export or cytoplasmic retention. (paudel2021themek5erk5pathway pages 1-2, fernandez2021resumendetesis. pages 68-72)
In the cytoplasm, ERK5 participates in survival and cytoskeletal or adhesion-associated signaling. In the nucleus, it phosphorylates transcriptional regulators and engages its C-terminal transactivation domain. Localization is dynamic and context-dependent; splice isoforms lacking parts of the tail may alter shuttling. Importantly, ATP-site inhibitors can themselves expose the NLS and drive nuclear entry, so nuclear ERK5 is not invariably evidence of normal upstream MEK5 activation. (fernandez2021resumendetesis. pages 64-68, cook2020smallmoleculeerk5 pages 9-11, lochhead2020paradoxicalactivationof pages 1-2)
The most compelling functional annotation is in vascular endothelium. Laminar shear stress and associated mitochondrial ROS activate MEK5–ERK5. ERK5–MEF2 signaling induces KLF2/KLF4-centered programs that favor endothelial quiescence, antioxidant capacity, apoptosis resistance, barrier integrity, and suppression of inflammatory and endothelial-to-mesenchymal-transition programs. NRF2 is another recurrent antioxidant output. (tusa2023pathophysiologicalimpactof pages 4-6, paudel2021themek5erk5pathway pages 3-5, wen2024boneandextracellular pages 15-16)
Genetics establishes that this role is not merely correlative. Global Erk5 or Mek5 knockout in mice disrupts heart and vessel development, angiogenesis, vessel maturation, and endothelial architecture, causing embryonic death at approximately E9.5–E10.5, with some reports extending the range to E11.5. Endothelial-selective deletion substantially reproduces the phenotype, whereas cardiomyocyte-selective deletion is much less severe. In adult mice, inducible loss causes vascular leakage, hemorrhage, extensive endothelial apoptosis, and death within approximately 2–4 weeks. These observations identify the endothelium—not a generic proliferation phenotype—as the strongest site of essential ERK5 function. (paudel2021themek5erk5pathway pages 3-5, wen2024boneandextracellular pages 5-6, drew2012mek5erk5pathwaythe pages 5-7)
ERK5 can phosphorylate or regulate BAD, SGK, FOXO-associated pathways, cyclin D1, and MEF2 programs, thereby influencing survival, cell-cycle entry, migration, and differentiation. However, these effects are conditional: dominant-negative or inhibitor experiments have shown strong effects in some endothelial or cancer models, whereas other fibroblast or KRAS/BRAF-mutant systems show little sustained proliferation dependence. A careful annotation is therefore that ERK5 is a stress-adaptive and fate-modulating signaling node, not a universally required mitogenic kinase. (paudel2021themek5erk5pathway pages 3-5, drew2012mek5erk5pathwaythe pages 5-7)
A 2023 review synthesized evidence that H₂O₂ and other ROS activate ERK5 through mechanisms involving calcium, SRC-family kinases, MEKK2/MEK5, receptor tyrosine kinases, and other context-specific components. ERK5 commonly promotes antioxidant responses through KLF2/KLF4 and NRF2, particularly in mechanically stressed endothelium. Nevertheless, protective versus pathogenic effects depend on tissue, dose, timing, and disease state. Tusa et al., published April 2023, DOI: https://doi.org/10.3390/cells12081154. (tusa2023pathophysiologicalimpactof pages 4-6)
ERK5 expression or activity has been associated with proliferation, EMT, invasion, angiogenesis, DNA-damage tolerance, and therapy adaptation in several cancers. In glioblastoma, a kinome-siRNA study identified ERK5 as a determinant of temozolomide response; ERK5 targeting impaired repair/survival after temozolomide, while higher expression correlated with higher tumor grade and poorer survival. This is preclinical target validation, not evidence of clinical efficacy. Carmell et al., published February 2021, DOI: https://doi.org/10.3390/cancers13050944. (carmell2021identificationandvalidation pages 7-9)
Evidence is not uniformly oncogenic. Some ERK5-amplified or RAS/RAF-mutant cells are not addicted to ERK5 for baseline proliferation, and transient knockdown effects may reflect adaptation. Open Targets lists literature-supported MAPK7 associations with cancer and breast carcinoma, but the reported aggregate association scores are modest (approximately 0.11–0.14) and should not be interpreted as clinical actionability. (OpenTargets Search: -MAPK7, paudel2021themek5erk5pathway pages 3-5)
Common research compounds include MEK5 inhibitors BIX02188/BIX02189 and ERK5-directed compounds XMD8-92, ERK5-IN-1/XMD17-109, AX15836, JWG-071, BAY-885, and related analogues. XMD8-92 has important bromodomain and other off-target activity; other series can affect LRRK2 or additional kinases. These molecules are useful probes only when target engagement, off-targets, and ERK5 transcriptional activity are measured separately. (fernandez2021resumendetesis. pages 77-80, cook2020smallmoleculeerk5 pages 9-11)
A major expert warning is paradoxical activation. Binding of several ATP-site inhibitors—including ERK5-IN-1-related compounds, AX15836, and BAY-885—to the kinase domain can trigger conformational opening, nuclear translocation, and C-terminal transcriptional activation despite suppression of catalytic activity. Selective inhibitors may therefore fail to phenocopy genetic ablation and can potentially stimulate part of the pathway they were intended to block. The authoritative mechanistic study was published in Nature Communications in March 2020, DOI: https://doi.org/10.1038/s41467-020-15031-3. (cook2020smallmoleculeerk5 pages 9-11, lochhead2020paradoxicalactivationof pages 2-3, lochhead2020paradoxicalactivationof pages 1-2)
The clinical-trial search retrieved no relevant interventional study directly targeting MAPK7/ERK5. TG02 has entered clinical development but is a broad multikinase inhibitor and cannot validate ERK5 as its operative human target. Accordingly, MAPK7 remains a preclinical therapeutic target, with no approved MAPK7-selective drug or demonstrated real-world ERK5-directed treatment implementation identified. (fernandez2021resumendetesis. pages 77-80, cook2020smallmoleculeerk5 pages 3-5)
Song et al. used H1 human pluripotent stem cells, two ERK5 inhibitors, MAPK7 shRNA, RNA sequencing, directed differentiation, rescue experiments, and teratoma assays. ERK5 disruption reduced NANOG-associated programs and expression of autocrine NODAL/TGF-β, WNT, FGF, and BMP components, suppressed mesoderm/endoderm specification, and favored ectodermal markers. Recombinant NODAL partially rescued NANOG and selected fate defects. Most reported experiments used three independent measurements; more than 90% of cells remained NANOG-positive after two days under maintenance conditions, and treated cultures retained teratoma-forming ability after five passages. These results support a role in balancing autocrine mitogenic signals rather than simply maintaining viability. Published September 2024, DOI: https://doi.org/10.1016/j.stemcr.2024.07.007. Limitations include predominantly in-vitro evidence, small replicate numbers, and dependence on pharmacological perturbation despite supporting shRNA experiments. (song2024erk5promotesautocrine pages 2-5, song2024erk5promotesautocrine pages 5-7)
Cultured chondrocytes exposed to low fluid shear stress (≤2 dyn/cm²) were protected from IL-1β-induced apoptosis. miR-143-3p mimics/inhibitors, ERK5 inhibition, and KLF4 overexpression supported a model in which low shear suppresses miR-143-3p and activates an ERK5–KLF4 protective axis. Published October 2024, DOI: https://doi.org/10.1186/s13018-024-05140-w. The evidence is mechanistically suggestive but remains cellular; the retrieved report did not provide sufficient sample-size or effect-size detail for clinical extrapolation. (zhao2024lowshearstress pages 1-2)
A multi-omics study analyzed 207 treatment-naïve specimens: 28 primary cutaneous melanomas, 81 acral melanomas, 28 mucosal melanomas, 27 metastatic melanomas, and 43 nevi. MAPK7–NF-κB upregulation was associated with increased T-cell recruitment and greater anti-PD-1 sensitivity in an independent treatment cohort. This supports MAPK7 as a potential immune-state biomarker, but does not show that pharmacological ERK5 inhibition would improve immunotherapy; indeed, inhibition could oppose a T-cell-recruiting state. Published July 2024, DOI: https://doi.org/10.1038/s41421-024-00688-7.
Recent work has explored ERK5-dependent metabolic adaptation in pediatric diffuse midline glioma, computational dual ERK1/ERK5 inhibitors, and network-based breast-cancer drug combinations. These remain preclinical or computational applications. Their principal value is hypothesis generation and identification of combination vulnerabilities, not evidence for an established therapy.
MAPK7/Q13164 is correctly identified as human ERK5/BMK1. Its primary function is to convert MEK5-mediated TEY phosphorylation into protein Ser/Thr phosphorylation, C-terminal autophosphorylation, regulated nuclear transport, and transcriptional control. The most defensible functional annotation emphasizes endothelial mechanotransduction and stress adaptation through MEF2–KLF2/KLF4/NRF2 programs, with indispensable roles in vessel development and integrity. Cancer, stem-cell, cartilage, and metabolic studies broaden this biology, but MAPK7-directed therapy remains experimental because catalytic inhibition does not capture all ERK5 functions and can paradoxically activate its transcriptional domain.
References
(fernandez2021resumendetesis. pages 64-68): A Sánchez Fernández. Resumen de tesis. the mek5/erk5 pathway in lung and ovarian cancer. Unknown journal, 2021.
(paudel2021themek5erk5pathway pages 1-2): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 118 citations.
(pearson2018regulationoferk5 pages 9-13): AJ Pearson. Regulation of erk5 function via its c terminus and its role in her2+ breast cancer. Unknown journal, 2018.
(tusa2023pathophysiologicalimpactof pages 4-6): Ignazia Tusa, Alessio Menconi, Alessandro Tubita, and Elisabetta Rovida. Pathophysiological impact of the mek5/erk5 pathway in oxidative stress. Cells, 12:1154, Apr 2023. URL: https://doi.org/10.3390/cells12081154, doi:10.3390/cells12081154. This article has 23 citations.
(paudel2021themek5erk5pathway pages 3-5): Rupesh Paudel, Lorenza Fusi, and Marc Schmidt. The mek5/erk5 pathway in health and disease. International Journal of Molecular Sciences, 22:7594, Jul 2021. URL: https://doi.org/10.3390/ijms22147594, doi:10.3390/ijms22147594. This article has 118 citations.
(fernandez2021resumendetesis. pages 68-72): A Sánchez Fernández. Resumen de tesis. the mek5/erk5 pathway in lung and ovarian cancer. Unknown journal, 2021.
(monti2022clinicalsignificanceand pages 1-2): Matilde Monti, Jacopo Celli, Francesco Missale, Francesca Cersosimo, Mariapia Russo, Elisa Belloni, Anna Di Matteo, Silvia Lonardi, William Vermi, Claudia Ghigna, and Emanuele Giurisato. Clinical significance and regulation of erk5 expression and function in cancer. Cancers, 14:348, Jan 2022. URL: https://doi.org/10.3390/cancers14020348, doi:10.3390/cancers14020348. This article has 37 citations.
(drew2012mek5erk5pathwaythe pages 2-4): Barbara A. Drew, Matthew E. Burow, and Barbara S. Beckman. Mek5/erk5 pathway: the first fifteen years. Biochimica et biophysica acta, 1825 1:37-48, Jan 2012. URL: https://doi.org/10.1016/j.bbcan.2011.10.002, doi:10.1016/j.bbcan.2011.10.002. This article has 283 citations.
(pearson2018regulationoferk5 pages 13-18): AJ Pearson. Regulation of erk5 function via its c terminus and its role in her2+ breast cancer. Unknown journal, 2018.
(drew2012mek5erk5pathwaythe pages 5-7): Barbara A. Drew, Matthew E. Burow, and Barbara S. Beckman. Mek5/erk5 pathway: the first fifteen years. Biochimica et biophysica acta, 1825 1:37-48, Jan 2012. URL: https://doi.org/10.1016/j.bbcan.2011.10.002, doi:10.1016/j.bbcan.2011.10.002. This article has 283 citations.
(lochhead2020paradoxicalactivationof pages 2-3): Pamela A. Lochhead, Julie A. Tucker, Natalie J. Tatum, Jinhua Wang, David Oxley, Andrew M. Kidger, Victoria P. Johnson, Megan A. Cassidy, Nathanael S. Gray, Martin E. M. Noble, and Simon J. Cook. Paradoxical activation of the protein kinase-transcription factor erk5 by erk5 kinase inhibitors. Nature Communications, Mar 2020. URL: https://doi.org/10.1038/s41467-020-15031-3, doi:10.1038/s41467-020-15031-3. This article has 63 citations and is from a highest quality peer-reviewed journal.
(cook2020smallmoleculeerk5 pages 9-11): Simon J. Cook, Julie A. Tucker, and Pamela A. Lochhead. Small molecule erk5 kinase inhibitors paradoxically activate erk5 signalling: be careful what you wish for…. Biochemical Society Transactions, 48:1859-1875, Sep 2020. URL: https://doi.org/10.1042/bst20190338, doi:10.1042/bst20190338. This article has 34 citations and is from a peer-reviewed journal.
(lochhead2020paradoxicalactivationof pages 1-2): Pamela A. Lochhead, Julie A. Tucker, Natalie J. Tatum, Jinhua Wang, David Oxley, Andrew M. Kidger, Victoria P. Johnson, Megan A. Cassidy, Nathanael S. Gray, Martin E. M. Noble, and Simon J. Cook. Paradoxical activation of the protein kinase-transcription factor erk5 by erk5 kinase inhibitors. Nature Communications, Mar 2020. URL: https://doi.org/10.1038/s41467-020-15031-3, doi:10.1038/s41467-020-15031-3. This article has 63 citations and is from a highest quality peer-reviewed journal.
(wen2024boneandextracellular pages 15-16): Lei Wen, Zirui Liu, Libo Zhou, Zhongcheng Liu, Qingda Li, Bin Geng, and Yayi Xia. Bone and extracellular signal-related kinase 5 (erk5). May 2024. URL: https://doi.org/10.3390/biom14050556, doi:10.3390/biom14050556. This article has 5 citations.
(wen2024boneandextracellular pages 5-6): Lei Wen, Zirui Liu, Libo Zhou, Zhongcheng Liu, Qingda Li, Bin Geng, and Yayi Xia. Bone and extracellular signal-related kinase 5 (erk5). May 2024. URL: https://doi.org/10.3390/biom14050556, doi:10.3390/biom14050556. This article has 5 citations.
(carmell2021identificationandvalidation pages 7-9): Natasha Carmell, Ola Rominiyi, Katie N. Myers, Connor McGarrity-Cottrell, Aurelie Vanderlinden, Nikita Lad, Eva Perroux-David, Sherif F. El-Khamisy, Malee Fernando, Katherine G. Finegan, Stephen Brown, and Spencer J. Collis. Identification and validation of erk5 as a dna damage modulating drug target in glioblastoma. Cancers, 13:944, Feb 2021. URL: https://doi.org/10.3390/cancers13050944, doi:10.3390/cancers13050944. This article has 17 citations.
(OpenTargets Search: -MAPK7): Open Targets Query (-MAPK7, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(fernandez2021resumendetesis. pages 77-80): A Sánchez Fernández. Resumen de tesis. the mek5/erk5 pathway in lung and ovarian cancer. Unknown journal, 2021.
(cook2020smallmoleculeerk5 pages 3-5): Simon J. Cook, Julie A. Tucker, and Pamela A. Lochhead. Small molecule erk5 kinase inhibitors paradoxically activate erk5 signalling: be careful what you wish for…. Biochemical Society Transactions, 48:1859-1875, Sep 2020. URL: https://doi.org/10.1042/bst20190338, doi:10.1042/bst20190338. This article has 34 citations and is from a peer-reviewed journal.
(song2024erk5promotesautocrine pages 2-5): Chengcheng Song, Zhaoying Zhang, Dongliang Leng, Ziqing He, Xuepeng Wang, Weiwei Liu, Wensheng Zhang, Qiang Wu, Qi Zhao, and Guokai Chen. Erk5 promotes autocrine expression to sustain mitogenic balance for cell fate specification in human pluripotent stem cells. Sep 2024. URL: https://doi.org/10.1016/j.stemcr.2024.07.007, doi:10.1016/j.stemcr.2024.07.007. This article has 3 citations and is from a domain leading peer-reviewed journal.
(song2024erk5promotesautocrine pages 5-7): Chengcheng Song, Zhaoying Zhang, Dongliang Leng, Ziqing He, Xuepeng Wang, Weiwei Liu, Wensheng Zhang, Qiang Wu, Qi Zhao, and Guokai Chen. Erk5 promotes autocrine expression to sustain mitogenic balance for cell fate specification in human pluripotent stem cells. Sep 2024. URL: https://doi.org/10.1016/j.stemcr.2024.07.007, doi:10.1016/j.stemcr.2024.07.007. This article has 3 citations and is from a domain leading peer-reviewed journal.
(zhao2024lowshearstress pages 1-2): Jun Zhao and Yayi Xia. Low shear stress protects chondrocytes from il-1β-induced apoptosis by activating erk5/klf4 signaling and negatively regulating mir-143-3p. Journal of Orthopaedic Surgery and Research, Oct 2024. URL: https://doi.org/10.1186/s13018-024-05140-w, doi:10.1186/s13018-024-05140-w. This article has 7 citations and is from a peer-reviewed journal.